Meeting Reports 2002

SLE: Targets for New Therapeutics Agenda

January 10-12, 2002 (historical)

Thursday, January 10, 2002

7:45-8:30 a.m.

Registration and Coffee
Crystal Ballroom Foyer

8:30 a.m.

Welcoming Remarks: Jane Salmon; Margaret Dowd and Susana Serrate-Sztein
Crystal Ballroom, Waterford/Lalique Suites

8:40 a.m.-12:00 noon: Session I: Extrinsic and Intrinsic Triggers of Autoimmunity
Crystal Ballroom, Waterford/Lalique Suites

Chair: David Pisetsky

  • David Pisetsky - The role of bacterial DNA in triggering anti-DNA production in SLE
  • Judith James -The role of EBV infection in the pathogenesis of SLE
  • Michael Lockshin - Speculations about the role of sex in SLE
  • Valerie Fadok - The interaction of apoptotic cells with the immune system
  • Westley Reeves - The pristane model of SLE
12:00 noon-1:30 p.m. Lunch and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites
1:30-5:30 p.m. Session II: Predisposing Factors: Genetics of SLE in Humans
Crystal Ballroom, Waterford/Lalique Suites
Chair: Brian Kotzin
  • Brian Kotzin - Identification of genes that promote murine lupus
  • Edward Wakeland - Identification of genes that suppress murine lupus
  • Mark Walport - SLE: A disease of disordered waste disposal
  • Timothy Behrens - Genetic fine mapping in human SLE
  • Lindsey Criswell - ACE polymorphisms in human SLE: importance of genetic heterogeneity
  • John Harley - Clinical variation holds genetic secrets of lupus
  • Betty Tsao - Follow-up linkage studies in SLE
5:30 p.m.-7:30 p.m. Dinner and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites
7:30-9:30 p.m. Evening Workshops
Basic Mechanisms I
Embassy Room
Chair: Gary Gilkeson and Joan Merrill
  • Bahram Namjou - Stratification of pedigrees multiplex for arthritis and systemic lupus erythematosus (SLE) detects an SLE susceptibility gene at 5p15.3
  • Silvia Bolland - Genetic modifiers of SLE in FcgammaRIIB-deficient mice
  • Susan Boackle - CR2, a candidate gene in the SLE1c lupus susceptibility locus, encodes a dysfunctional protein in the NZM2410 mouse
  • Elahna Paul - C4 deficiency attenuates the central regulation of autoreactive B cells
  • Yu Yang - A quantitative genetic trait for human lupus: low and high gene dosages of complement C4 in SLE patients
  • Guillermina Girardi - Complement activation mediates antiphopholipid antibody (apl-ab)- induced pregnancy loss
  • Hong Zhou - Induction of monocyte tissue factor expression and activity by IgG from patients with the antiphospholipid syndrome and inhibition by Dilazep, an adenosine uptake inhibitor
Basic Mechanisms II
Severn Suite
Chair: Joseph Craft and George Tsokos
  • Florin Niculescu - Increased phosphatidylinositol-3 kinase (PI 3-kinase) and JNK1 activity is a feature of the pathogenic T cells in a murine model of lupus
  • Wendy Davidson - Evidence for Fas-dependent and Fas-independent caspase-independent oncotic cell death pathways in T cells that are triggered by TCR ligation
  • Jun-Qi Yang- Functional insufficiency of NKT cells in lupus: studies in CD1d-knockout NZB/NZW F1 mice
  • Douglas Lienesch -Renal, splenic and circulatory TGF-beta levels in mouse models of SLE
  • Dama Laxminarayana - Mutations in protein kinase A (PKA) RI-alpha gene transcripts and upregulation of mRNA editing gene expression in SLE T lymphocytes.
  • Violeta Rus - Gene expression analysis of cytokine and chemokine-related genes in PBMC from lupus patients in disease flare and remission
  • Nilamadhab Mishra - Histone deacetylase inhibitors are the candidates for the treatment of Systemic Lupus Erythematosus
Basic Mechanisms III
Judiciary Suite
Chair: Mary Crow and Bruce Richardson.
  • Randy Cron - Identification of a novel GATA-regulated CD154 transcriptional enhancer
  • Mariana Kaplan - Multiple death-receptor pathways mediate APC cytotoxicity induced by autoreactive lupus T cells
  • Virginia Pascual - IFN-a: a novel therapeutic target in SLE
  • Krishnan Sundar - Induction of antibodies to dsDNA and Sm in mice immunized with EBNA-1 expressing plasmids
  • Andrew Gross - High numbers of Epstein Barr Virus infected B lymphocytes in the peripheral blood of patients with Systemic Lupus Erythematosus
  • Allison Reiss - Serum from SLE patients compromises cholesterol homeostasis in cultured human aortic endothelial cells (HAEC) by decreasing cholesterol 27-hydroxylase expression
  • Vivian Ng - Antibodies to domain II/III of apolipoprotein A1: correlation to atherosclerotic factors in a lupus cohort
Epidemiology/Genetics/Clinical Features
Susquehanna Suite
Chair: Rosalind Ramsey-Goldman and Matthew Liang
  • Glinda Cooper - Occupational exposures and risk of Systemic Lupus Erythematosus
  • Victoria Werth - Strong association of a promoter polymorphism of tumor necrosis factor- alpha (TNF-alpha) with a photosensitive form of cutaneous lupus erythematosis
  • Christine Parks - Systemic Lupus Erythematosus and genetic polymorphisms in IL-1alpha, IL-1beta and IL-1 receptor antagonist: a population-based case-control study
  • Brad Rovin - A novel interleukin-8 (IL-8) polymorphism is associated with severe SLE nephritis
  • Sarah Thielman - Predominance of continued activity with advancing chronicity in serial renal biopsies from patients with lupus nephritis
  • Joan Merrill - Registry for the Antiphospoholipid Syndrome: association of antiphospholipid antibodies with post-menopausal arterial events
  • Sasha Bernatsky - A meta-analysis of clinical cohort studies of malignancy in lupus
Treatment: Murine and Human Studies
Cabinet Suite
Chair: David Horowitz and Dafna Gladman
  • S.G. Zheng - Suppression of a lupus-like syndrome in mice with regulatory T cells generated ex-vivo with Transforming Growth Factor-beta
  • T. Zhou - An agonistic anti-human DR5 antibody as a potential therapeutic agent in SLE
  • Lena Schiffer - Remission of SLE nephritis induced by short-term combination costimulatory blockade in NZB/W F1 mice is associated with downregulation of expression of the chemokine BLC
  • Juergen Foell - Immune intervention in the pathogenesis of SLE by means of the CD137 (4-1BB) signaling pathway
  • Amrie Grammer - Analysis of peripheral B cells following treatment of active SLE patients with humanized anti-CD154 MAB (5C8,BG9588).
  • Gregg Silverman - Development of B-cell superantigen therapy for SLE
  • D. Alarcon-Segovia - SLE trial shows fewer renal flares in LJP 394-treated patients with high-affinity antibodies to LJP 394

Friday, January 11, 2002

8:30 a.m. - 12:00 noon Session III: Immunoregulatory Mechanisms
Crystal Ballroom, Waterford/Lalique Suites
Chair: Katherine Siminovitch
  • Bevra Hahn - Immunoregulatory abnormalities in SLE
  • Katherine Siminovitch - Roles of SH2 domain containing tyrosine phosphatases in modulating lymphocyte activation
  • Joseph Craft - Mechanisms of loss of T cell tolerance in SLE
  • John O'Shea - Cytokine signaling and immunodeficiency
  • Jane Gross - Role of BLyS and its receptors TAC1 and BCMA in B cell development and regulation of autoimmune disease
  • Peter Lipsky - B cells in SLE
12:00 noon - 2:00 p.m. Lunch and Poster Sessions
Crystal Ballroom, Haverford/Baccarat Suites
2:00 p.m. - 5:30 p.m. Session IV: Mediators of Tissue Injury
Crystal Ballroom, Waterford/Lalique Suites
Chair: Jane Salmon
  • Jane Salmon - Complement activation as a mediator of anti-phospholipid antibody-induced injury
  • Jose-Carlos Gutierrez-Ramos - Genomic approaches for identifying mediators of tissue injury
  • Betty Diamond - A model for CNS injury in SLE
  • Mark Ginsberg - Alpha 4 integrins and leukocyte trafficking
  • Charles Esmon - Thrombosis as a target of inflammatory-mediated injury
  • Daniel Kastner - Mendelian disorders of inflammation
5:30 p.m.-7:30 p.m. Dinner and Poster Session
Crystal Ballroom, Haverford/Baccarat Suites
7:30 p.m. - 9:30 p.m.

Evening Plenary Session:
Drug Trials and Tribulations
Crystal Ballroom, Waterford/Lalique Suites

Saturday, January 12, 2002
8:30 a.m. - 12:00 noon Session V: Novel Therapies
Crystal Ballroom, Waterford/Lalique Suites
Chair: David Wofsy
  • James Balow - Cytotoxic therapy for lupus nephritis
  • David Daikh - Targeting active immune responses in SLE by inhibition of T cell costimulation
  • Robert Eisenberg - Targeting B cells in SLE
  • Richard Quigg - Treatment of SLE by inhibition of complement activation
  • Michelle Petri - High-dose cyclophosphamide for SLE
  • Ann Traynor - Immune diversity post-transplant: a mechanism for achieving organ repair
12:00 noon